Recent developments in targeting ras downstream effectors for ras-driven cancer therapy

HIGHLIGHTS

• who: Ozge Tatli and Gizem Dinler Doganay from the Department of Molecular Biology, Genetics-Biotechnology, Graduate School, Istanbul Technical University, Department of Molecular Biology and Genetics, Istanbul Medeniyet University, Istanbul, Turkey have published the article: Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy, in the Journal: Molecules 2021, 26, 7561 LY3214996 of /2021/
• how: These results showed that inhibiting the PI3K-mTOR pathway would potentiate the effectiveness of KRASG12C covalent inhibitors and provide a therapeutic opportunity for patients with KRASG12C mutations in combined settings.
• future: In the near future . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.